Charlie Mills Net Worth 2026: How the Medline Chairman Built $11B

Quick answer

Charlie Mills is worth an estimated $11 billion in 2026, according to Forbes, which ranked him No. 141 on the 2026 Forbes 400 list of richest Americans (published September 15, 2026; net worths as of September 4). He is the chair of Medline Industries, the Northfield, Illinois-based medical-supply giant his father and uncle founded in 1966 — and essentially his entire fortune is his stake in that one company.

Mills, 65, is a newcomer to the Forbes 400. His debut came on the back of Medline's December 2025 IPO, which raised $6.26 billion — the largest IPO anywhere in the world in 2025 — and finally put a public market price on the family's decades-old private holding. He served as Medline's CEO for 26 years (1997–2023) before becoming chairman, growing sales from roughly $600 million to more than $25 billion a year.

The $11 billion fortune, broken down

Forbes does not publish a line-item breakdown of Mills' holdings, but the structure of his wealth is unusually simple for a man worth $11 billion: it is almost entirely Medline equity. There are no headline-grabbing side empires — no tech startups, no sports teams, no crypto bets. One company, built over 60 years, did all of it.

That concentration is the story. When Medline was private — from 1977 until December 2025 — the family's wealth existed mostly on paper, valued by Forbes against comparable public companies with a liquidity discount. The IPO converted it into something countable: 216 million shares priced at $29, with the stock closing its first day at $41, up about 41%.

A Forbes 400 debut 60 years in the making

The 2026 Forbes 400 was published on September 15, 2026, with net worths measured as of September 4 — and the cutoff to make the list had climbed to a record $4.4 billion, up from $3.8 billion the year before. Charlie Mills cleared it easily at $11 billion, landing at No. 141.

He was one of three Medline family members to debut on the 2026 list, alongside his cousin Andy Mills (No. 311, $5.5 billion) and Wendy Abrams (No. 367, $4.7 billion), Jon Mills' daughter. Two more relatives — Andy's sister Nancy and another sister, Margaret — are also billionaires from their Medline stakes but fell just below the $4.4 billion cutoff. For a fuller comparison of the two cousins, see Charlie Mills vs Andy Mills net worth.

Forbes' methodology values stakes in private companies against comparable public firms with a 10% liquidity discount — but for Mills, that no longer matters. His company is public now, and his fortune moves with the MDLN ticker like any other shareholder's.

The IPO that made it official: $6.26 billion, December 2025

On December 16, 2025, Medline priced its offering at $29 a share — near the top of its $26–$30 range — selling 216 million shares to raise $6.26 billion. It was the largest IPO of 2025 anywhere in the world, surpassing even big-ticket listings in Hong Kong, and the largest U.S. IPO since Rivian's 2021 debut.

The market's reaction was emphatic. Medline shares, trading on the Nasdaq Global Select Market under the symbol MDLN, opened at $35 and closed their first day at $41 — about 41% above the offer price — valuing the company at more than $38 billion at pricing, per MarketWatch. CEO Jim Boyle rang the opening bell as the medical-supply maker that had been private for nearly five decades rejoined the public markets.

At the time of the IPO, Mills' net worth was estimated at $10.9 billion; by the time Forbes published the 2026 Forbes 400 nine months later, it had ticked up to $11 billion. Read how Charlie Mills made his money for the full journey from $600 million in sales to that debut.

From $600 million to $25.5 billion: the 26-year run

When Jim and Jon Mills handed the reins to the next generation in 1997, Medline was a respected but mid-sized medical-supply company doing a little over $600 million in annual sales. Charlie Mills, then in his mid-30s with a Cornell MBA, became CEO; his cousin Andy became president; and Andy's brother-in-law Jim Abrams became COO.

What followed was one of the great quiet compounding runs in American business. By the company's prospectus, Medline has now logged more than 50 consecutive years of annual sales growth. Revenue passed $20 billion a year in 2021 and reached $25.5 billion in 2024. The workforce grew from about 23,000 employees in 2019 to 43,000 by the IPO, and the catalog swelled past 300,000 medical-surgical products sold in more than 100 countries.

Mills stepped down as CEO in 2023 after 26 years and became chairman — the fourth generation of the family to run a business whose roots trace to 1910, when his grandfather Irv Mills ran Mills Hospital Supply.

The $34 billion buyout that set the table

Four years before the IPO, in June 2021, private-equity heavyweights Blackstone, Carlyle Group, and Hellman & Friedman acquired a majority stake in Medline in a leveraged buyout valued at roughly $34 billion — one of the largest LBOs in healthcare history. The Mills family rolled its equity into the deal and remained Medline's largest single shareholder, with the entire senior management team staying in place.

The buyout mattered for the fortune in two ways. First, it established a credible $34 billion valuation benchmark for the business. Second, it professionalized the capital structure — the IPO proceeds were earmarked largely for debt repayment and equity redemptions — so that when Medline finally went public, the family's retained stake converted cleanly into listed shares. For the complete corporate picture, see what companies Charlie Mills owns.

The family wealth map

The Medline fortune is a family fortune, spread across the descendants of the two founding brothers. The 2026 Forbes 400 captured the three largest holders:

Charlie's stake is roughly double his cousin Andy's — the gap reflects the ownership split between the two founding brothers' branches of the family, with the exact percentages never publicly disclosed. Jim Mills died in 2019; Jon Mills' side of the family holds the next-largest blocks.

What moves the number from here

With Medline now public, Charlie Mills' net worth is, for the first time in his life, a number you can watch move in real time. It rises and falls with the MDLN share price — the same market forces that lifted it from $10.9 billion at the IPO to $11 billion by September 2026. Dividends, any future share sales, and the company's continued growth (or contraction) will all show up in the Forbes tally.

One thing that won't change the number: a salary. Medline was private for nearly all of Mills' 26 years as CEO, so his compensation was never disclosed — and as Charlie Mills' salary breakdown shows, the paycheck was never the point. The $11 billion came from owning the machine, not from running it for a wage.

Frequently asked questions